BTG Gains CE Mark for Drug-Eluting Bead
BTG has received Class III CE Mark certification for DC Bead LUMI, which is a radiopaque drug-eluting bead.
The bead can be loaded with doxorubicin or irinotecan for the local treatment of tumors in patients with hepatocellular carcinoma and malignant colorectal cancer metastasized to the liver.
The bead provides real-time confirmation of bead location, enhancing the level of control in transarterial chemoembolisation procedures. — Cynthia Jessup